Pricing Log in Create free account
Saturday 17 October 2026 Export OMER’s income statement to Excel — free account

Omeros Corporation

OMER Healthcare Biotechnology

In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.

16.20 2.59 −13.78%
Market cap
$1.4B
P/E
9.5×
Fwd P/E
2.1×
Dividend yield
—
F-score
2/9
Altman Z
−6.82
Beneish M
−0.06
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Omeros Corporation (OMER) Business Profile

Updated before January 2025

Company Overview

Omeros Corporation (NASDAQ: OMER) is a biopharmaceutical company headquartered in Seattle, Washington. Founded in 1994 by Dr. Gregory A. Demopulos, who currently serves as the Chairman and Chief Executive Officer, Omeros focuses on discovering, developing, and commercializing small-molecule and protein therapeutics. The company’s mission is to address unmet medical needs across a range of therapeutic areas, including inflammation, immunology, and central nervous system disorders. Over the years, Omeros has built a robust pipeline of innovative products and has established itself as a leader in the biopharmaceutical industry.

Core Business Segments

Omeros Corporation operates primarily in the biopharmaceutical sector, with a focus on the following core business segments:

1. Inflammation and Immunology

Omeros has developed therapies targeting inflammation and immune-related disorders. The company’s flagship product in this segment is OMIDRIA® (phenylephrine and ketorolac intraocular solution), which is used during cataract surgery or intraocular lens replacement to maintain pupil size and reduce postoperative pain. OMIDRIA has been a significant revenue driver for the company.

2. Central Nervous System (CNS) Disorders

Omeros is actively developing treatments for CNS disorders, including schizophrenia and Huntington’s disease. The company’s lead candidate in this area is OMS824, a phosphodiesterase 10 (PDE10) inhibitor, which is being evaluated for its potential to treat cognitive and motor impairments associated with these conditions.

3. Complement-Related Disorders

Omeros is advancing its research in complement-related disorders through its MASP-2 (mannan-binding lectin-associated serine protease-2) and MASP-3 programs. The lead product candidate in this segment is narsoplimab (OMS721), a human monoclonal antibody targeting MASP-2. Narsoplimab is being developed for the treatment of thrombotic microangiopathies (TMAs), IgA nephropathy, and other complement-mediated diseases.

4. Preclinical and Early-Stage Programs

Omeros also has a pipeline of preclinical and early-stage programs targeting a variety of diseases, including cancer, metabolic disorders, and infectious diseases. These programs leverage the company’s proprietary platforms and expertise in drug discovery.

Business Model

Omeros Corporation’s business model is centered around the discovery, development, and commercialization of innovative therapeutics. The company generates revenue primarily through the sale of OMIDRIA and aims to expand its revenue streams by bringing additional products to market. Omeros invests heavily in research and development (R&D) to advance its pipeline of drug candidates and secure regulatory approvals. The company also collaborates with academic institutions and industry partners to accelerate drug discovery and development.

Omeros employs a vertically integrated approach, managing all aspects of the drug development process, from discovery to commercialization. This strategy allows the company to maintain control over its intellectual property and ensure the quality and efficacy of its products.

Strategic Direction

Omeros Corporation is focused on achieving long-term growth through the following strategic initiatives:

  • Pipeline Expansion: The company is committed to advancing its pipeline of drug candidates, with a particular emphasis on narsoplimab and other complement-related therapies.
  • Global Market Penetration: Omeros aims to expand its presence in international markets by securing regulatory approvals and establishing distribution partnerships.
  • Sustainability Goals: The company is exploring ways to minimize its environmental footprint and promote sustainable practices in its operations.
  • Innovation: Omeros continues to invest in cutting-edge research and technology to develop novel therapeutics and address unmet medical needs.

Competitive Landscape

Omeros operates in a highly competitive biopharmaceutical industry, where it faces competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Alexion Pharmaceuticals (AstraZeneca): A leader in complement-related therapies, particularly in the treatment of rare diseases.
  • Regeneron Pharmaceuticals: Known for its innovative monoclonal antibody therapies.
  • Horizon Therapeutics: Focused on rare and rheumatic diseases.
  • Biogen: A major player in CNS disorders, including Alzheimer’s and multiple sclerosis.

Despite the competition, Omeros differentiates itself through its proprietary platforms, innovative pipeline, and focus on niche therapeutic areas.

Risk Factors

Omeros Corporation faces several risks that could impact its business operations and financial performance:

  • Market Dependence: The company relies heavily on OMIDRIA for revenue generation, making it vulnerable to market fluctuations and competitive pressures.
  • Regulatory Challenges: Delays or failures in obtaining regulatory approvals for its drug candidates could hinder the company’s growth.
  • Supply Chain Disruptions: Disruptions in the supply chain could affect the production and distribution of OMIDRIA and other products.
  • Financial Risks: As a clinical-stage company, Omeros incurs significant R&D expenses and may require additional funding to support its operations.
  • Litigation Risks: The company is exposed to potential legal and intellectual property disputes.

Recent Developments

Omeros has made significant progress in advancing its pipeline and corporate strategy:

  • Narsoplimab Developments: The company has reported positive clinical trial results for narsoplimab in the treatment of IgA nephropathy and other complement-mediated diseases.
  • OMIDRIA Sales Growth: Omeros has achieved strong sales growth for OMIDRIA, driven by increased adoption among ophthalmic surgeons.
  • Partnerships: The company has entered into strategic collaborations to accelerate the development of its drug candidates.
  • COVID-19 Impact: Omeros has navigated the challenges posed by the COVID-19 pandemic, ensuring the continuity of its operations and clinical trials.

Investment Considerations

Investors considering Omeros Corporation should weigh the following strengths and risks:

Strengths

  • Robust pipeline of innovative drug candidates.
  • Strong revenue growth from OMIDRIA.
  • Proprietary platforms and expertise in drug discovery.
  • Focus on niche therapeutic areas with high unmet medical needs.

Risks

  • Heavy reliance on a single product (OMIDRIA) for revenue.
  • High R&D expenses and potential funding requirements.
  • Regulatory and competitive challenges.
  • Exposure to market and supply chain risks.

Conclusion

Omeros Corporation is a dynamic biopharmaceutical company with a strong focus on innovation and addressing unmet medical needs. While the company faces challenges, such as market dependence and regulatory hurdles, its robust pipeline and strategic initiatives position it for long-term growth. With continued investment in R&D and a commitment to expanding its global presence, Omeros is well-positioned to capitalize on emerging opportunities in the biopharmaceutical industry.